Alloy Women’s Health has launched a Weight Care Program designed specifically for women in perimenopause and menopause. The program offers three GLP-1 medication options: FDA-approved Wegovy and Zepbound, as well as compounded liraglutide, all with transparent pricing to address cost barriers.
“After sleep and mood disruption, menopausal weight gain is the most common complaint we hear from our customers,” says Anne Fulenwider, Alloy Co-Founder and Co-CEO. “For so many women, eating healthily and exercising regularly just doesn’t work as well as they did when they were younger.”
The program includes lifestyle support, 24/7 doctor access, progress tracking, support groups, and Menopausal Hormone Therapy. Dr. Michelle Montville, Clinical Director, notes, “Emerging research shows that GLP-1 medications may work even better when combined with menopausal hormone therapy. Estrogen plays a key role in maintaining muscle, bone, and metabolism.”
Monica Molenaar, Alloy Co-Founder and Co-CEO, explains their approach: “We picked the name ‘Alloy’ because an alloy is a combination of powerful elements to create something stronger. We offer the right combinations of medications to meet women’s specific needs, including the potent combination that can help maintain weight and even reverse health issues like high blood pressure and inflammation.”
According to the company, this expansion comes amid significant company growth, with new customers increasing 245% year-over-year and sales growing 193% as Alloy diversifies beyond hormone therapy into skincare, haircare, sexual wellness, gut health, and now weight management.
